Lead Product(s) : Lorazepam
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Mylan Group
Deal Size : Undisclosed
Deal Type : Partnership
Pfizer Partners with Mylan for Marketing of Ativan and Pacitane
Details : The partnership aims for the marketing and sale of two of pfizer's brands, Ativan (lorazepam) to treat anxiety disorders and Pacitane to treat Parkinson's disease.
Product Name : Ativan
Product Type : Controlled Substance
Upfront Cash : Undisclosed
February 24, 2025
Lead Product(s) : Lorazepam
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Mylan Group
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Lorazepam
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Hôpital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lorazepam is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of Coma.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 12, 2024
Lead Product(s) : Lorazepam
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Hôpital Universitaire de Bruxelles | ZonMw | Belgium Health Care Knowledge Centre
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lorazepam,Tofacitinib Citrate
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : National Institutes of Health
Deal Size : $5.3 million
Deal Type : Funding
Details : The funding will be used in the randomized controlled trial which will investigate the safety and effectiveness of three different treatments for Down syndrome regression disorder. Lorazepam is an anti-anxiety medication that treats catatonia and other s...
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
January 25, 2023
Lead Product(s) : Lorazepam,Tofacitinib Citrate
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : National Institutes of Health
Deal Size : $5.3 million
Deal Type : Funding
Lead Product(s) : Lorazepam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lorazepam Effects on Neuroimaging Measures
Details : Lorazepam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 17, 2020
Lead Product(s) : Lorazepam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lorazepam
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
Details : Lorazepam is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anxiety Disorders.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
December 03, 2014
Lead Product(s) : Lorazepam
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lorazepam for the Treatment of Status Epilepticus or Repetitive Status Epilepticus in Japan
Details : Lorazepam is a Controlled Substance drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Status Epilepticus.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 12, 2014
Lead Product(s) : Lorazepam
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lorazepam is a Controlled Substance drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
November 26, 2013
Lead Product(s) : Lorazepam
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lorazepam
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
ADASUVE-Lorazepam Drug-Drug Interaction
Details : Lorazepam is a Controlled Substance drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 14, 2013
Lead Product(s) : Lorazepam
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Lorazepam
Therapeutic Area : Undisclosed
Study Phase : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lorazepam is a Controlled Substance drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
January 10, 2011
Lead Product(s) : Lorazepam
Therapeutic Area : Undisclosed
Highest Development Status : Undisclosed
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
